Adding of sitagliptin phosphate hydrate to combination therapy with pegylated interferon alpha 2b and ribavirin for patients with chronic hepatitis C and diabetes mellitus

Trial Profile

Adding of sitagliptin phosphate hydrate to combination therapy with pegylated interferon alpha 2b and ribavirin for patients with chronic hepatitis C and diabetes mellitus

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Sitagliptin (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Diabetes mellitus; Hepatitis C
  • Focus Therapeutic Use
  • Acronyms ASPIRIN
  • Most Recent Events

    • 06 Nov 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 08 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top